BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alavi M, Poustchi H, Merat S, Kaveh-Ei S, Rahimi-Movaghar A, Shadloo B, Hajarizadeh B, Grebely J, Dore GJ, Malekzadeh R. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. Int J Drug Policy 2019;72:99-105. [PMID: 31303262 DOI: 10.1016/j.drugpo.2019.07.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Yousafzai MT, Alavi M, Valerio H, Hajarizadeh B, Grebely J, Dore GJ. Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia. Viruses 2022;14:1496. [PMID: 35891474 DOI: 10.3390/v14071496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ortiz-paredes D, Amoako A, Ekmekjian T, Engler K, Lebouché B, Klein MB. Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review. Front Public Health 2022;10:877585. [DOI: 10.3389/fpubh.2022.877585] [Reference Citation Analysis]
3 Tasavon Gholamhoseini M, Sharafi H, Hl Borba H, Alavian SM, Sabermahani A, Hajarizadeh B. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study. BMJ Open 2022;12:e058757. [PMID: 35676019 DOI: 10.1136/bmjopen-2021-058757] [Reference Citation Analysis]
4 Mirzazadeh A, Hosseini-hooshyar S, Shahesmaeili A, Sharafi H, Shafiei M, Zarei J, Mousavian G, Tavakoli F, Ghalekhani N, Shokoohi M, Khezri M, Mehmandoost S, Shojaei MR, Karamouzian M, Briceno A, Morris MD, Alavian SM, Haghdoost A, Sharifi H, Page KA. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. International Journal of Drug Policy 2022;102:103580. [DOI: 10.1016/j.drugpo.2022.103580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ortiz-paredes D, Amoako A, Lessard D, Engler K, Lebouché B, Klein MB. Potential interventions to support HCV treatment uptake among HIV co-infected people in Canada: Perceptions of patients and health care providers. CanLivJ 2022;5:14-30. [DOI: 10.3138/canlivj-2021-0021] [Reference Citation Analysis]
6 Dhiman RK, Grover GS, Premkumar M, Roy A, Taneja S, Duseja A, Arora S; MMPHCRF Investigators. Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model. EClinicalMedicine 2021;41:101148. [PMID: 34712928 DOI: 10.1016/j.eclinm.2021.101148] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hariri S, Davari S, Malekzadeh Z, Mohammadi Z, Masoudi S, Gandomkar A, Amini-Kafiabad S, Maghsoudloo M, Merat S, Poustchi H, Malekzadeh F. Prevalence of Hepatitis B and C Infections and Associated Risk Factors in Pars Cohort Study, Southern Iran. Middle East J Dig Dis 2021;13:95-102. [PMID: 34712446 DOI: 10.34172/mejdd.2021.211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Generaal E, Logtenberg van der Grient H, Schatz E, van Santen DK, Boyd A, Woods SK, Baak BLC, Prins M. A Feasibility Study to Increase Chronic Hepatitis C Virus RNA Testing and Linkage to Care among Clients Attending Homeless Services in Amsterdam, The Netherlands. Diagnostics (Basel) 2021;11:1197. [PMID: 34209440 DOI: 10.3390/diagnostics11071197] [Reference Citation Analysis]
9 A H, L M, Am J, M M, Gp A, S V. Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis. Int J Drug Policy 2021;:103342. [PMID: 34210551 DOI: 10.1016/j.drugpo.2021.103342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
10 Ohata PJ, Su Lwin HM, Han WM, Khwairakpam G, Tangkijvanich P, Matthews GV, Avihingsanon A. Elimination of hepatitis C among HIV-positive population in Asia: old and new challenges. Future Virology 2021;16:407-417. [DOI: 10.2217/fvl-2021-0015] [Reference Citation Analysis]
11 Bajis S, Applegate TL, Grebely J, Matthews GV, Dore GJ. Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. J Infect Dis 2020;222:S758-72. [PMID: 33245354 DOI: 10.1093/infdis/jiaa366] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
12 Malekzadeh R, Poustchi H. Hepatocellular Cancer in Iran. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_14] [Reference Citation Analysis]
13 Alavi M, Moghanibashi-Mansourieh A, Radfar SR, Alizadeh S, Bahramabadian F, Esmizade S, Dore GJ, Sedeh FB, Deilamizade A. Coordination, cooperation, and creativity within harm reduction networks in Iran: COVID-19 prevention and control among people who use drugs. Int J Drug Policy 2021;93:102908. [PMID: 32819776 DOI: 10.1016/j.drugpo.2020.102908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Hariri S, Sharafkhah M, Alavi M, Roshandel G, Fazel A, Amiriani T, Motamed-Gorji N, Bazazan A, Merat S, Poustchi H, Malekzadeh R. A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting. Harm Reduct J 2020;17:56. [PMID: 32795371 DOI: 10.1186/s12954-020-00400-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
15 Mirzazadeh A, Hosseini-Hooshyar S, Shahesmaeili A, Bahramnejad A, Barshan A, Mousavian G, Najafi E, Sharifi H, Haghdoost AA, Briceno A, McFarland W, Page K. Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran. Subst Abuse Treat Prev Policy 2020;15:56. [PMID: 32758246 DOI: 10.1186/s13011-020-00298-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
16 Draper BL, Pedrana A, Howell J, Yee WL, Htay H, Aung KS, Shilton S, Kyi KP, Naing W, Hellard M. Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study. JMIR Res Protoc 2020;9:e16863. [PMID: 32673260 DOI: 10.2196/16863] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
17 Draper BL, Pedrana A, Howell J, Yee WL, Htay H, Aung KS, Shilton S, Kyi KP, Naing W, Hellard M. Decentralized, Community-Based Hepatitis C Point-of-Care Testing and Direct-Acting Antiviral Treatment for People Who Inject Drugs and the General Population in Myanmar: Protocol for a Feasibility Study (Preprint).. [DOI: 10.2196/preprints.16863] [Reference Citation Analysis]
18 Anushiravani A, Ghajarieh Sepanlou S. Burden of Liver Diseases: A Review from Iran. Middle East J Dig Dis 2019;11:189-91. [PMID: 31824620 DOI: 10.15171/mejdd.2019.147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
19 Grebely J, Hajarizadeh B, Lazarus JV, Bruneau J, Treloar C; International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy 2019;72:1-10. [PMID: 31345644 DOI: 10.1016/j.drugpo.2019.07.016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]